Chronic Obstructive Pulmonary Disease Assessment Test Can Predict Depression: A Prospective Multi-Center Study

Young Seok Lee,1 Sunghoon Park,2 Yeon-Mok Oh,3 Sang-Do Lee,3 Sung-Woo Park,2 Young Sam Kim,6 Kwang Ho In,5 Bock Hyun Jung,7 Kwan Ho Lee,3 Seung Won Ra,3 Yong Il Hwang,2 Yong-Bum Park,9 Ki-Suck Jung,2 and Korean COPD Study Group

This study was conducted to investigate the association between the chronic obstructive pulmonary disease (COPD) assessment test (CAT) and depression in COPD patients. The Korean versions of the CAT and patient health questionnaire-9 (PHQ-9) were used to assess COPD symptoms and depressive disorder, respectively. In total, 803 patients with COPD were enrolled from 32 hospitals and the prevalence of depression was 23.8%. The CAT score correlated well with the PHQ-9 score ($r = 0.631; P < 0.001$) and was significantly associated with the presence of depression ($\beta \pm$ standard error, $0.452 \pm 0.020; P < 0.001$). There was a tendency toward increasing severity of depression in patients with higher CAT scores. By assessment groups based on the 2011 Global Initiative for Chronic Obstructive Lung Disease guidelines, the prevalence of depression was affected more by current symptoms than by airway limitation. The area under the receiver operating characteristic curve for the CAT was 0.849 for predicting depression, and CAT scores $\geq 21$ had the highest accuracy rate (80.6%). Among the eight CAT items, energy score showed the best correlation and highest power of discrimination. CAT scores are significantly associated with the presence of depression and have good performance for predicting depression in COPD patients.

Key Words: Pulmonary Disease, Chronic Obstructive; COPD Assessment Test; Depression

INTRODUCTION

Depression is a major comorbidity in COPD and is associated with higher rates of acute exacerbation, re-admission, and 30-day mortality (1-4). Clinical depression has a reported prevalence of 10% to 42% in COPD patients (4-6) and can be a high economic burden to society (1, 2). Therefore, early detection of depression and appropriate intervention are important (3, 7). In previous studies, severe dyspnea, low body mass index, female gender, low lung function, poor performance status, and current smoking were identified as risk factors for depression in COPD patients (5, 6, 8). Additionally, several well-known parameters, including an index reflecting the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE in-
Lee YS, et al. • COPD Assessment Test and Depression

The CAT is a validated and patient-completed questionnaire comprising eight items: cough, phlegm, chest tightness, breathlessness going up hills/stairs, activity limitation at home, confidence leaving home, sleep, and energy. The score for each CAT item ranges from 0 to 5. The CAT score is known to be well correlated with the St. George’s Respiratory Questionnaire score (12, 13, 20). The 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends that clinicians use the CAT to assess current symptoms and assign patients to treatment groups based on a CAT scores < 10 vs ≥ 10. The Korean version of the CAT has recently been validated (21).

Data analysis
To evaluate the predictive usefulness of the CAT for depression in COPD patients, correlation analysis, multiple linear regression analysis, and receiver operating characteristics (ROC) curve analysis were performed. The sensitivity, specificity, positive predictive value (PV), and negative PV of CAT scores for predicting depression were calculated. The frequency of depression was determined according to age; the GOLD classification of airway limitation based on FEV₁ as a percentage of the predicted value (FEV₁/% ≥ 80% vs 50% to < 80% vs 30% to < 50% vs < 30%); and the CAT score groups (≤ 9 vs 10-20 vs 21-30 vs ≥ 31). Depression severity was compared using multi-nominal logistic regression analysis. We also compared the frequency of depression among the assessment groups (Groups A, B, C, and D) based on the 2011 GOLD guidelines (i.e., CAT scores [< 10 vs ≥ 10] for symptoms and FEV₁/% [≥ 50% vs < 50%] for future risk) (14).

Correlation analysis, ROC curve analysis, and logistic regression analysis were performed to determine which items of the CAT are the best predictors of depression in COPD patients. Continuous data are expressed as means ± standard deviation, and categorical data are expressed as the number (percentage). Chi-square test was used for the comparison of categorical data. P values < 0.05 indicated statistical significance. All statistical analyses were performed using SAS statistical software, EG version (SAS Institute, Inc., Cary, NC, USA).

Ethics statement
The study protocol was approved by the institutional review board at each participating hospital (Hallym University Sacred Heart Hospital, IRB No. 2010-1061). Written informed consent was obtained from each patient.

RESULTS
A total of 803 patients were enrolled during the study period,
and 91.4% were male. The mean age was 68.2 ± 8.2 yr, and the mean FEV₁% was 52.0 ± 19.4% (Table 1). The prevalence of depression, defined as a PHQ-9 score ≥ 10, was 23.8%. The mean CAT score was 16.2 ± 8.4. Female patients experienced depression more often than male patients, but the difference was not statistically significant. The prevalence of depression was significantly higher in elderly patients than in young patients (P = 0.019; Fig. 1).

### Prevalence of depression according to treatment groups by the 2011 GOLD guidelines

For the assessment and treatment of COPD patients, the 2011 GOLD recommends that patients should be divided into four groups: Group A (low risk and less symptoms), Group B (low risk and more symptoms), Group C (high risk and less symptoms), and Group D (high risk and more symptoms). In the present study, the prevalence rates of depression were 1.8%, 32.0%, 2.7%, and 28.8% in Groups A, B, C, and D, respectively (Fig. 2). The prevalence differed according to current symptoms (Groups A and C vs Groups B and D; P < 0.001), but not future risk (Groups A and B vs Groups C and D; P = 0.955).

### Table 1. Patient demographics and clinical characteristics

| Variables | Subjects (n = 803) |
|-----------|-------------------|
| Male      | 734 (91.4)        |
| Age (yr)  | 68.2 ± 8.2        |
| FEV₁ (% of predicted value) | 52.0 ± 19.4 |
| GOLD stage |                 |
| Mild      | 67 (8.3)          |
| Moderate  | 352 (43.8)        |
| Severe    | 296 (36.9)        |
| Very severe | 88 (11)        |
| Depression (PHQ-9 score ≥ 10) | 191 (23.8) |
| CAT score | 16.2 ± 8.4        |

Data is presented as mean ± standard deviation or number (percentage). CAT, COPD assessment test; FEV₁, forced expiratory volume in 1 second; GOLD, global initiative for chronic obstructive lung disease; PHQ-9, Patient Health Questionnaire-9.
Associations of CAT score and GOLD classification of airway limitation with depression

As shown in Fig. 3, the prevalence of depression did not differ among the four groups based on the GOLD classification of airway limitation. Among groups stratified by CAT score (≤ 9 vs 10-20 vs 21-30 vs ≥ 31), the frequency of depression was significantly higher in the group with higher CAT scores (P < 0.001 and P < 0.001 by chi-square test and linear-by-linear association, respectively), and patients with higher CAT scores tended to have more severe depression (Table 2).

In the correlation analysis, a significant correlation was found between the PHQ-9 and CAT scores (r = 0.631 and P < 0.001), but not between the PHQ-9 and GOLD classification of airway limitation (Fig. 4). In the multiple linear regression analysis with age, gender, FEV1, and CAT score as covariates, the CAT score had a significant association with the depression score (β ± standard error, 0.452 ± 0.020; P < 0.001; Table 3).

**Table 2.** Odds ratio of GOLD classification and CAT groups for each severity of depression

| Levels of Depression Severity by PHQ-9 Score* | GOLD Classification of airway limitation | CAT Groups |
|---------------------------------------------|----------------------------------------|------------|
|                                             | OR‡ | 95% CI‡ | OR† | 95% CI† |
| 0 to 9                                      | –   | –       | –   | –       |
| 10 to 14 (mild)                             | 0.894 | 0.678-1.181 | 4.500 | 3.228-6.274 |
| 15 to 19 (moderate-to-severe)               | 0.881 | 0.642-1.209 | 7.297 | 4.896-10.867 |
| ≥ 20 (severe)                               | 0.921 | 0.589-1.440 | 12.799 | 7.162-22.874 |

*Depression is defined as a PHQ-9 score of ≥ 10 in the present study; †By multi-nominal logistic regression analyses; ‡Goodness-of-fit test: Chi-square = 2.913 and P = 0.820.

**Table 3.** Multiple linear regression analysis of the association between CAT score and depression

| Variables | β   | SE  | t     | P   |
|-----------|-----|-----|-------|-----|
| Age       | 0.004 | 0.020 | 0.220 | 0.826 |
| Sex       | -0.435 | 0.582 | -0.747 | 0.465 |
| FEV1 (%)  | 0.024 | 0.009 | 2.792 | 0.005 |
| CAT score | 0.452 | 0.020 | 22.848 | < 0.001 |
| Constant  | -2.312 | 1.491 | -1.551 | 0.121 |

CAT, COPD assessment test; FEV1, forced expiratory volume in 1 second; SE, standard error.

**Fig. 4.** Scatter diagrams showing the correlations between two parameters. (A) Correlation between Patient Health Questionnaire-9 (PHQ-9) and COPD assessment test (CAT). (B) Correlation between PHQ-9 and forced expiratory volume in 1 second (FEV1).

**Fig. 5.** Receiver operating characteristic (ROC) curve for the COPD assessment test (CAT) score for predicting depression (the Patient Health Questionnaire-9 score ≥ 10). The area under the curve (AUC) was 0.849 (95% confidence interval, 0.819 to 0.880; P < 0.001).
Table 4. Sensitivity and specificity of CAT score for predicting depression in COPD patients

| CAT Score | Sensitivity (%) | Specificity (%) | (+) PV (%) | (-) PV (%) | Accuracy (%) |
|-----------|----------------|----------------|------------|------------|--------------|
| Total score |                |                |            |            |              |
| ≥ 10      | 97.9           | 30.1           | 30.4       | 97.9       | 46.2         |
| ≥ 21      | 69.1           | 84.0           | 57.4       | 89.7       | 80.6         |
| ≥ 31      | 20.4           | 98.7           | 83.0       | 79.9       | 80.1         |
| ≥ 19*     | 78.0           | 77.5           | 51.9       | 91.7       | 77.6         |

*Optimal cutoff value by the receiver operating characteristic (ROC) curve. CAT, COPD assessment test; COPD, chronic obstructive pulmonary disease; PV, predictive value.

Table 5. Correlation analysis and AUC values between CAT and PHQ-9 scores

| CAT items | r* | AUC values (95% CI) | OR (95% CI) |
|-----------|----|--------------------|-------------|
| Cough     | 0.318 | 0.676 (0.630 to 0.722) | 1.554 (1.379 to 1.751) |
| Phlegm    | 0.258 | 0.661 (0.614 to 0.708) | 1.508 (1.337 to 1.701) |
| Chest tightness | 0.435 | 0.738 (0.697 to 0.779) | 1.783 (1.590 to 2.000) |
| Breathlessness going up hills/stairs | 0.383 | 0.718 (0.678 to 0.758) | 1.979 (1.690 to 2.317) |
| Activity limitation at home | 0.493 | 0.772 (0.734 to 0.810) | 1.861 (1.666 to 2.078) |
| Confidence leaving home | 0.531 | 0.775 (0.736 to 0.813) | 1.881 (1.685 to 2.099) |
| Sleep | 0.502 | 0.766 (0.725 to 0.807) | 1.921 (1.712 to 2.156) |
| Energy | 0.535 | 0.793 (0.756 to 0.830) | 2.547 (2.162 to 3.000) |
| Total sum of the eight items | 0.631 | 0.849 (0.819 to 0.880) | - |

*Correlation coefficients by Pearson’s correlation analysis; †Area under the receiver operating characteristic (ROC) curves for the presence of depression (PHQ-9 score of ≥ 10); ‡Odds ratios for the presence of depression (PHQ-9 score of ≥ 10). AUC, area under the curve; CAT, COPD assessment test; CI, confidence interval; OR, odds ratio; PHQ-9, Patient Health Questionnaire-9.

**Ability of the sum of CAT scores to predict depression**

The ability of the CAT scores to predict the presence of depression was investigated using ROC curve analysis (Fig. 5). The AUC for the CAT score was 0.849 (95% confidence interval, 0.819 to 0.880), and the optimal cutoff value was ≥ 19.0. The sensitivity, specificity, (+) PV, (-) PV, and accuracy are shown in Table 4. The sensitivity and specificity of the optimal cutoff value (≥ 19) were 78.0 and 77.5, respectively, but the accuracy was highest (80.6%) for a CAT score ≥ 21.

**Association of CAT items with depression**

The correlation coefficients, AUC values, and odds ratios (ORs) of each CAT item for the presence of depression (PHQ-9) are shown in Table 5. Among the eight CAT items, chest tightness, activity limitation at home, confidence leaving home, sleep, and energy scores showed fair correlations (0.4 ≤ r < 0.6) and discrimination power (0.7 ≤ AUC < 0.8). Among these five items, the energy score had the best correlation and the highest AUC value, which was comparable to that of the total CAT score. In particular, the OR of the energy score for the presence of depression was significantly higher than those of the other seven CAT items.

**DISCUSSION**

The present study had several important findings. First, the CAT score was significantly associated with depression, with good predictive usefulness for the presence of depression in COPD patients. Second, compared with the GOLD classification of airway limitation, the CAT score was better correlated with the depression score, and depression severity was higher in patients with higher CAT scores. Among the assessment groups based on the 2011 GOLD guidelines, the frequency of depression differed by current symptoms, but not by the severity of the airway limitation. Finally, among the eight items of the CAT, the energy score showed the best correlation with the presence of depression and had the highest discrimination power.

Depression has been extensively studied and is known to have a negative impact on COPD outcomes (4, 9, 10). However, depression often goes undiagnosed, and its exact prevalence and mechanisms in COPD are unclear. In previous studies, several composite markers have been evaluated. However, these markers are too complex for routine use in outpatient settings. In 2011, the GOLD recommended the use of the CAT for assessment of COPD patients (13, 14). It is a valid tool and simple to use. Therefore, in the present study, we investigated usefulness of the CAT for prediction of depression in COPD patients in an outpatient setting.

Among the four variables included in the multivariate analysis in our study, the CAT score was significantly associated with presence of depression. ROC curve analysis indicated good performance of the CAT score for predicting depression. The 2011 GOLD guidelines recommend a CAT score of ≥ 10.0 for assigning COPD patients to a treatment group (14). However, in the present study, the (+) PV of CAT scores ≥ 10.0 for presence of depression was only 30.4%. At an optimal cutoff value of ≥ 19.0, sensitivity and specificity were 78.0 and 77.5, respectively, and accuracy rate was the highest (80.6%) using a cutoff value of...
≥ 21.0. Therefore, based on our results, a higher CAT score, possibly ≥ 21.0, would be more useful for depression screening in COPD patients. In addition, we also investigated association between individual items of the CAT and depression. Chest tightness, activity limitation at home, confidence leaving home, sleep, and energy scores were correlated with depression. Among these, energy score showed the highest correlation and good discrimination power. Thus, rather than traditional COPD symptoms (i.e., cough and phlegm), these five CAT items, especially energy, may be better indicators of depression in COPD patients.

The prevalence of depression in our study population was 23.8%, and depression was more common in elderly patients than in young patients. There was no difference in prevalence between genders or between severities of airflow limitation. In contrast, the ECLIPSE study reported that depression was significantly associated with young age and female gender, and severe airflow limitation (6). This discrepancy between the ECLIPSE study and ours may be attributable to several differences between the study populations, including differences in gender, age, and disease severity distributions, or may be a consequence of the different tools used for assessment and analysis (5). In the present study, depression was observed at all grades of GOLD classification of airflow limitation. Several previous studies have also demonstrated depression even in mild-grade COPD, and we emphasized the need for early screening to reduce the risk for acute exacerbation (22-24). However, in our study, the presence of depression was dependent on current symptoms, and not on lung function. Additionally, we also demonstrated the increased severity of depression with higher CAT scores (Fig. 2 and Table 2). Thus, regardless of results of lung function tests, physicians should quickly assess the presence of depression in all COPD patients and particularly in symptomatic patients. Using the CAT, physicians may be able to assess not only patients’ current symptoms but also potential depression.

Our study had several limitations. First, we did not investigate other variables such as comorbidities, exacerbation frequency, and smoking status that have associations with depression in COPD patients (5, 6). As a result, we could not include other potential variables in the multivariate model. Second, among several depression scales, the PHQ-9 was used in the present study. Although the reliability and validity of the PHQ-9 have not been extensively studied in COPD, it is the most commonly used scale in primary care. Finally, the CAT has items which are originally associated with depression, such as energy and sleep. Therefore, the superiority of the CAT over the GOLD classification in the present study may be attributable to the structure itself of the questionnaire. Despite these limitations, our nationwide, multi-center study is, to our knowledge, the first demonstration of the usefulness of the CAT for depression screening in COPD patients. According to many experts, a better understanding of the barriers to the diagnosis and treatment of depression in COPD patients will improve outcomes (5, 25). Because of its simplicity and practicality, the CAT may be a useful tool for overcoming some barriers.

In conclusion, the CAT scores are significantly associated with the presence of depression and have good performance for predicting depression in COPD patients. Therefore, the CAT may be a useful tool for depression screening in out-patient settings. Large-scale, multi-center studies are needed to further define the role of the CAT for depression screening in COPD patients.

ACKNOWLEDGMENTS

The copyright of Korean version of CAT belongs to the GlaxoSmithKline (GSK) and the authors were allowed to use CAT for this study.

We would like to thank people below for their help: Kyung Ho Kang, Department of Internal Medicine, Korea University College of Medicine, Seoul; Sang Hak Lee, Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Seoul; Seong Yong Lim, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul; Kwang Ha Yoo, Department of Internal Medicine, Konkuk University Hospital, Seoul; In-Won Park, Department of Internal Medicine Chung-Ang University College of Medicine, Seoul; Myung Jae Park, Department of Internal Medicine, Kyung Hee University Hospital, Seoul; Jin Hwa Lee, Division of Pulmonary and Critical Care Medicine, Ewha Womans University School of Medicine, Seoul; Ji-Hyun Lee, Department of Internal Medicine, Pochon CHA University, Seongnam; Hye Sook Choi, Dongguk University College of Medicine, Gyeongju Hospital, Gyeongju; Jin Woo Kim, Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Uijeongbu; Jong Pil Jeong and Youngchun Ko, Department of Internal Medicine Kwangju Christian Hospital, Kwangju; Hye Yoon Park, Department of Internal Medicine, Sungkyunkwan University School of Medicine, Seoul; Hui Jung Kim, Department of Internal Medicine, Wonkwang University Sanbon Hospital, Gunpo; Kye Chul Shin, Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju; Myung-Goo Lee, Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital, Chuncheon; Hun Gyu Hwang, Eun-Jung Jung and Gune-II Lim, Division of Pulmonology Department of Internal Medicine, Soonchunhyang University Gumi Hospital, Gumi; Jong Deog Lee, Gyeongsang National University, School of Medicine, Jinju; Yong Ho Roh, Seoul Veterans Hospital, Seoul; Yang Deok Lee, Department of Internal Medicine, Eulji University School of Medicine, Daejeon; Hyong-Kyu Yoon, Department of Internal Medicine, The Catholic University of Korea, Seoul; Ju-Ock Kim and Jeong Eun Lee, Pulmonology section, Department of Internal Medicine, Chungnam National Univer-
The authors have no conflicts of interest to disclose.

REFERENCES

1. Abrams TE, Vaughan-Sarrazin M, Van der Weg MW. Acute exacerbations of chronic obstructive pulmonary disease and the effect of existing psychiatric comorbidity on subsequent mortality. Psychosomatics 2011; 52: 441-9.

2. Dalal AA, Shah M, Lunacek O, Hanania NA. Clinical and economic burden of depression/dyspnea in chronic obstructive pulmonary disease patients within a managed care population. COPD 2011; 8: 293-9.

3. Jennings JH, Digiovine B, Obeid D, Frank C. The association between depressive symptoms and acute exacerbations of COPD. Lung 2009; 187: 128-35.

4. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007; 167: 60-7.

5. Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, Hanania NA; ACCP Workshop Panel on Anxiety and Depression in COPD. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 2008; 134: 435-56S.

6. Hanania NA, Müllerova H, Locantore NW, Vestbo J, Watkins ML, Wouters EF, Rennard SI, Sharafkhaneh A; Evaluation of COPD Longitudinal Observations and Results (ECLIPSE) Study Investigators. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011; 183: 604-11.

7. Von Leupoldt A, Taube K, Lehmann K, Fritzschke A, Magnusson H. The impact of anxiety and depression on outcomes of pulmonary rehabilitation in patients with COPD. Chest 2011; 140: 730-6.

8. Al-shair K, Dockry R, Mallia-Milanes B, Kolsum U, Singh D, Vestbo J. Depression and its relationship with poor exercise capacity, BODE index and muscle wasting in COPD. Respir Med 2009; 103: 1572-9.

9. Balcels E, Gea J, Ferrer J, Serra I, Orozco-Lévi M, de Batlle J, Rodriguez E, Benet M, Donaire-González D, Antó JM, et al. Factors affecting the relationship between psychological status and quality of life in COPD patients. Health Qual Life Outcomes 2010; 8: 108.

10. Ito K, Kawayaama T, Shoji Y, Fukushima N, Matsunaga K, Edakuni N, Uchimura N, Hoshino T. Depression, but not sleep disorder, is an independent factor affecting exacerbations and hospitalization in patients with chronic obstructive pulmonary disease. Respirology 2012; 17: 940-9.

11. Kii SV, Oh WO, Koo BJ, Suk MH. Relationship between depression and health-related quality of life in older Korean patients with chronic obstructive pulmonary disease. J Clin Nurs 2010; 19: 1307-14.

12. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J 2009; 34: 648-54.

13. COPD Assessment Test. Available at http://www.catestonline.org [accessed on 1 January 2011].

14. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PN, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-65.

15. Hwang YI, Lee YS, Oh YM, Lee SD, Park SW, KimYS, In KH, Jung BH, Lee KH, Ra SW, et al. Prevalence of depression and its influence on health-related quality of life in COPD patients. Chest 2011; 140: 542A.

16. Han C, Jo SA, Kwak JH, Pae CU, Steffens D, Jo I, Park MH. Validation of the Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan Geriatric Study. Compr Psychiatry 2008; 49: 218-23.

17. Huang FY, Chung H, Kroenke K, Delucchi KL, Spitzer RL. Using the Patient Health Questionnaire-9 to measure depression among racially and ethnically diverse primary care patients. J Gen Intern Med 2006; 21: 547-52.

18. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16: 606-13.

19. Lamers F, Jonkers CC, Bosma H, Penninx BW, Kootmerus JA, van Eijk JT. Summed score of the Patient Health Questionnaire-9 was a reliable and valid method for depression screening in chronically ill elderly patients. J Clin Epidemiol 2008; 61: 679-87.

20. Ringbaek T, Martinez G, Lange P. A comparison of the assessment of quality of life with CAT, CCQ, and SGRQ in COPD patients participating in pulmonary rehabilitation. COPD 2012; 9: 12-5.

21. Lee S, Lee JS, Song JW, Choi CM, Shim TS, Kim TB, Cho YS, Moon HB, Lee SD, Oh YM. Validation of the Korean version of chronic obstructive pulmonary disease assessment test (CAT) and dyspnea-12 questionnaire. Tuberc Respir Dis 2010; 69: 171-6.

22. Chavannes NH, Huibers MJ, Schermer TR, Hendriks A, van Weel C, Wouters EE; van Schayck CP. Associations of depressive symptoms with gender, body mass index and dyspnea in primary care COPD patients. Fam Pract 2005; 22: 604-7.

23. De S. Prevalence of depression in stable chronic obstructive pulmonary disease. Indian J Chest Dis Allied Sci 2011; 53: 33-5.

24. Di Marco F, Verga M, Reggerente M, Maria Casanova F, Santus P, Blasi F, Allegra L, Centanni S. Anxiety and depression in COPD patients: the roles of gender and disease severity. Respir Med 2006; 100: 1767-74.

25. Pincus HA, Hough L, Houtsinger JK, Rollman BL, Frank RG. Emerging models of depression care: multi-level (‘6 P’) strategies. Int J Methods Psychiatr Res 2003; 12: 54-63.